Myriad Genetics, Inc. (MYGN) Tops Q2 EPS by 4c, Boosts Guidance
Tweet Send to a FriendGet Alerts MYGN Hot Sheet
Trade MYGN Now!
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q2 EPS of $0.42, $0.04 better than the analyst estimate of $0.38. Revenue for the quarter came in at $149.1 million versus the consensus estimate of $143.71 million.
Myriad Genetics, Inc. sees FY2013 EPS of $1.55-1.58, versus the consensus of $1.54. Myriad Genetics, Inc. sees FY2013 revenue of $575-585 million, versus prior guidance of $570-585 million and the consensus of $580.06 million.
For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Myriad Genetics, Inc. sees FY2013 EPS of $1.55-1.58, versus the consensus of $1.54. Myriad Genetics, Inc. sees FY2013 revenue of $575-585 million, versus prior guidance of $570-585 million and the consensus of $580.06 million.
For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- La-Z-boy, Inc. (LZB) Tops Q4 EPS by 5c
- Lentuo International (LAS) Swings to Q1 Loss; Updates on Expansion
- BofA/Merrill Lynch Downgrades Myriad Genetics (MYGN) to Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
